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Objectives: This systematic review aimed to investigate the prevalence 
and characteristics of vestibular adverse effects of aminoglycoside (AG) 
therapy in humans and to analyze objective vestibular tests for the detec-
tion of AG-induced vestibulotoxicity.
Design: PubMed, Cochrane Database, Web of Science, and reference 
lists of all included studies were screened by two independent research-
ers. The Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines were followed. Studies were included 
according to preset inclusion criteria and reported outcomes of studies 
evaluating vestibular function using one or more objective vestibular 
function tests in adults and children after systemic AG administration. 
The methodological quality of each study was assessed using the quality 
assessment tool for quantitative studies. Interrater reliability was estab-
lished using Cohen’s Kappa.
Results: Twenty-seven studies were included, with the vast majority 
showing AG-induced vestibulotoxic side effects, ranging from 0 to 60%. 
Most studies reported AG-induced abnormalities by caloric and rotatory 
testing, whereas only a few studies reported using video Head Impulse 
test and vestibular evoked myogenic potential testing.
Conclusions: Because type I hair cells (particularly of the semicircular 
canals) are more susceptible to ototoxicity, video Head Impulse test and 
vestibular evoked myogenic potential testing seem more promising for 
the early detection of vestibulotoxicity than caloric and rotatory testing. 
Prospective studies using an extensive vestibular test battery are needed 
to further characterize the impact of AGs on the different vestibular end 
organs and to identify the most sensitive vestibular technique for the 
early detection of vestibulotoxicity.
Key words: Aminoglycosides, Ototoxicity, Systematic review, Vestibular, 
Vestibular screening, Vestibulotoxicity.
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INTRODUCTION
Aminoglycosides (AG) are broad-spectrum antibiotics that 
are commonly prescribed in life-threatening diseases, such as 
multidrug-resistant tuberculosis, sepsis, and cystic fibrosis, 
due to their antimicrobial efficiency, widespread availability 
and cost-effectiveness (Gibson et al. 2003; Pillers & Schleiss 
2005; Schatz et al. 2005; Caminero et al. 2010). Since the use 
of streptomycin, the first discovered AG, it became clear that 
AGs may induce nephro- and ototoxicity (Hinshaw et al. 1947). 
Despite the recognized risk for these side effects, AGs are still 
frequently administered (Price 1986; Grohskopf et al. 2005; 
Hermann 2007). The overall reported incidence of AG-induced 
ototoxicity varies from 2 to 25% (Fee 1980; Esterhai et al. 
1986; Rizzi & Hirose 2007). Based on histological studies, AGs 
induce sensory hair cell injury. Prolonged exposure of inner ear 
cells to AGs is associated with destruction of outer hair cells 
in the organ of Corti and type I vestibular hair cells in both the 
crista ampullaris and maculae, leading to auditory and vestibu-
lar impairment (Huizing & de Groot 1987; Chiodo & Alberti 
1994; Forge & Schacht 2000; Carey et al. 2002; Lyford-Pike 
et al. 2007). The pathogenesis of AG-induced hair cell injury 
remains elusive. Several hypotheses have been reported (Forge 
& Schacht 2000; Rizzi & Hirose 2007; Selimoglu 2007; Poirrier 
et al. 2010) with oxidative stress considered to be the principal 
mechanism. Literature suggests that cellular injury depends on 
AG binding with iron to form a toxic metabolite, which gener-
ates hydroxyl radicals that place the cell under oxidative stress 
(Rizzi & Hirose 2007; Selimoglu 2007; Poirrier et al. 2010), 
resulting in apoptotic cell death. Although all AGs may dam-
age both cochlear and vestibular structures, individual AGs dif-
fer in their propensity to produce cochleo- or vestibulotoxicity. 
Neomycin, kanamycin, and amikacin are more cochleotoxic, 
whereas vestibular damage is generally triggered by gentamicin 
and streptomycin (Matz 1993; Selimoglu et al. 2003; Rybak & 
Ramkumar 2007).
The clinical features of AG-induced cochleotoxicity are 
frequently discussed (Rybak & Ramkumar 2007; Prayle et al. 
2010; Schacht et al. 2012; Chen et al. 2013; Farzal et al. 2016). 
Because outer hair cells at the cochlear base are more suscep-
tible to toxicity than apical hair cells, high frequencies are gen-
erally more severely affected (Fausti et al. 1984) resulting in a 
high-frequency sensorineural hearing loss, often accompanied 
by tinnitus. With continued exposure, hair cell damage pro-
gresses to the apex, placing patients at increased risk for fur-
ther hearing impairment (Huizing & de Groot 1987). Distortion 
product otoacoustic emissions and high-frequency audiometry 
are internationally recommended as the most sensitive tests 
for cochleotoxicity (Tange et al. 1985; Stavroulaki et al. 1999; 
Al-Malky et al. 2015; Geyer et al. 2015; Farzal et al. 2016).
Vestibulotoxicity from systemic AGs in humans is less fre-
quently described, which may be due to the presenting symp-
toms of vestibulotoxicity. Both ears are often affected, resulting 
in oscillopsia, chronic disequilibrium, and postural instability 
(Black & Pesznecker 1993; Ward et al. 2013; van de Berg et al. 
2015; Lucieer et al. 2016), symptoms which are often underap-
preciated by clinicians as relating to the ear, compared with tin-
nitus or spinning vertigo. These symptoms of vestibulotoxicity 
are often attributed to the underlying diseases, for which AGs 
were prescribed, and are often discovered late because patients 
receiving AG therapy are often bedridden. Finally, vestibular 
organ failure may be masked by sensory substitution by vision 
and proprioception, obscuring vestibular damage compared 
with the more salient effects of cochlear damage (van de Berg 
et al. 2015).
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Cochlear and vestibular dysfunctions can influence aca-
demic performance, social, cognitive, and mental development 
(Davis et al. 1986; van de Berg et al. 2015), which may result in 
a diminished quality of life (Mendel et al. 1999; Guinand et al. 
2012; Sun et al. 2014; Stevenson et al. 2015). Therefore, routine 
screening for audiovestibular side effects should be conducted 
during (and after) AG therapy, such that AG administration 
can be stopped or adjusted in time to prevent ototoxic damage 
(Black et al. 2001; Ariano et al. 2008; Leis et al. 2015). In con-
trast to the monitoring of cochleotoxic effects, there is no stan-
dardized protocol to screen for AG-induced vestibulotoxicity.
The aim of this systematic review is to determine the prev-
alence and characteristics of vestibular adverse effects of AG 
therapy in humans and to analyze objective vestibular techniques 
for early detection of systemic AG-induced vestibulotoxicity.
MATERIALS AND METHODS
This study was performed according to the international 
Preferred Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) guidelines (Liberati et al. 2009).
Search Strategy
A systematic literature search was conducted using PubMed, 
Web of Science, and Cochrane databases. The search strategy was 
based on keywords derived from the PICOS approach (Partici-
pants, Intervention, Comparison, Outcome, and Study design). 
The articles had to report outcomes of vestibular function evalu-
ation using one or more objective vestibular function tests (O) in 
adults and children (P) (before and) after systemic AG adminis-
tration (I). Because of the limited amount of data on vestibulo-
toxicity, all types of group designs (C and S) were accepted. The 
keywords used for the literature search are represented in Table 1.
Study Selection
Based on the selection criteria (Table 2), the title and abstract of 
all retrieved articles were screened, followed by a full-text screen-
ing of the selected articles. If the study did not meet the selection 
criteria, the article was excluded. An additional “hand search” was 
conducted by screening the reference lists of all included stud-
ies, to prevent missing useful citations. The literature search and 
screening procedure was conducted by two independent research-
ers, with calculation of Cohen’s Kappa score (Landis & Koch 
1977) to determine the level of interrater agreement. The cut-off 
date for articles to be included was November 2016.
Data Extraction
The following items were collected from each included 
study: author and year, study design, patient information 
(sample size, sex ratio, mean age, and pathology/infection for 
which AGs were prescribed), information about control group, 
information about AG use (applied AG, dose, duration, and 
manner of administration), additional cochlear toxicity, objec-
tive vestibular function tests (choice of test and time of evalua-
tion), vestibular outcome measures, main findings on vestibular 
symptoms and tests, as well as recommendations for screening.
Risk of Bias Assessment and Level of Evidence
The methodological quality of all included articles was 
evaluated using The Quality Assessment Tool For Quantitative 
Studies (developed by the Effective Public Health Practice Proj-
ect; Thomas et al. 2004), which rates six methodological study 
parameters: selection bias, study design, potential confounding 
variables (predetermined before bias assessment was started), 
blinding, data collection methods, and withdrawals and drop-
outs. The overall study quality was considered to be “strong” 
if none of the parameters was rated as “weak,” “moderate” if 
one parameter was rated as “weak,” and “weak” if two or more 
parameters were rated as “weak” (EPHPP 2009a, b). The overall 
TABLE 1. Keywords used for the literature search in PubMed, Web of Science, and the Cochrane database
Aminoglycoside ototoxicity AND “description A” Aminoglycoside ototoxicity AND “description B”
Neomycin AND “description A” Neomycin AND “description B”
Netilmicin AND “description A” Netilmicin AND “description B”
Streptomycin AND “description A” Streptomycin AND “description B”
Amikacin AND “description A” Amikacin AND “description B”
Tobramycin AND “description A” Tobramycin AND “description B”
Gentamicin AND “description A” Gentamicin AND “description B”
Aminoglycoside AND “description A” Aminoglycoside AND “description B”
Description A = (ocular vestibular-evoked myogenic potential OR 
oVEMP OR collic vestibular-evoked myogenic potential OR cVEMP 
OR rotational chair test OR rotary chair test OR rotatory OR caloric 
OR electronystagmography OR head impulse test)
Description B = (vestibulotoxicity OR ototoxicity vestibular OR 
ototoxicity saccule OR ototoxicity utricle OR ototoxicity  
semicircular canal)
TABLE 2. Inclusion and exclusion criteria in the selection 
procedure
Inclusion criteria
1.  Relating to patients receiving aminoglycoside antibiotics by 
systemic administration
2.  Including standard vestibular outcomes on at least one of the 
following function tests: rotatory test, caloric test, cervical or 
ocular vestibular evoked myogenic potential test, (video) head 
impulse test
3. A publication date from 1955 to 2016
4. Human studies
5. Articles published in the English language
Exclusion criteria
1.  Concerning cochlear toxicity only or as the main focus of the 
study
2. Concerning nephrotoxicity only
3. Biochemical studies
4.  Systematic reviews, meta-analyses, narrative reviews, case 
reports, editorials, and meeting abstracts
5. Duplicate data published in other included papers
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methodological quality score was not used as criterion for eli-
gibility because of the limited existing literature on this topic. 
However, bias assessment was conducted to enhance the consis-
tency of the results and to reveal further information about flaws 
in the literature. Additionally, the level of evidence was deter-
mined for each article and its study design based on the Oxford 
Centre for Evidence-based Medicine-Levels of Evidence guide-
lines (Phillips et al. 2009).
RESULTS
A total of 1361 records were retrieved from the electronic 
databases (Pubmed: 658; Cochrane Database: 38; Web of Sci-
ence: 665). A summary of the search results and reasons for 
exclusion are depicted in Figure 1. The percentage of interra-
ter agreement between the 2 investigators was high (95.9%), 
yielding a very good interrater agreement kappa score of 0.814 
(SE = 0.039; Landis & Koch 1977).
Characteristics of the Included Studies
The 27 studies consisted of randomized controlled trials (n = 2), 
a controlled clinical trial (n = 1), prospective cohort studies (n = 12), 
cross-sectional studies (n = 9), and retrospective case series (n = 3), 
all of which are represented in Supplemental Digital Content 1 
(http://links.lww.com/EANDH/A351). The publication year ranged 
from 1973 (Elfving et al. 1973; Tjernström et al. 1973) to 2016 
(Ahmed et al. 2016). The sample size of the study participants var-
ied from 10 (Gendeh et al. 1993) to 418 (Kim et al. 2011). The 27 
relevant articles comprised a total of 1675 patients treated with AGs. 
The mean age ranged from 2.4 days (Finitzo-Hieber et al. 1979) to 
70.0 years (Ahmed et al. 2011). A detailed description of the study 
characteristics is represented in Supplemental Digital Content 1 
(http://links.lww.com/EANDH/A351).
Risk of Bias Assessment and Level of Evidence
As measured by the Effective Public Health Practice Project 
tool (Thomas et al. 2004), 2 (7%) studies were rated as strong 
(Fee 1980; Lerner et al. 1986), 10 (37%) as moderate (Lehm-
ann et al. 1976; Finitzo-Hieber et al. 1979; Barza et al. 1980; 
Pedersen et al. 1987; Gendeh et al. 1993, 1991; Black et al. 
2004; Zagólski 2008; Ahmed et al. 2011; Kim et al. 2011) and 
15 (56%) as weak (Elfving et al. 1973; Tjernström et al. 1973, 
1982; Noone et al. 1974; Deka et al. 1977; Winkel et al. 1978; 
Eviatar & Eviatar 1981; Hauch et al. 1986; Aust 2001; Ishiyama 
et al. 2006; Scheenstra et al. 2009; Weber et al. 2009; Agrawal et 
al. 2013; Chen et al. 2013; Ahmed et al. 2016). Ratings for each 
individual parameter of the tool are represented in Supplemen-
tal Digital Content 2 (http://links.lww.com/EANDH/A352).
Thirteen of the 15 studies that rated weak were mainly 
due to the lack of appropriate consideration of predetermined 
potential confounders (i.e., age, gender, renal insufficiency, pre-
existing audiovestibular dysfunction, duration of AG therapy, 
total daily dose, previous AG exposure, and coadministration of 
other agents). The second significant reason for the weak rating 
was study design and this was evident in 10 of the 15 studies; 
cross-sectional studies and case series were automatically con-
sidered as weak. Studies with a high dropout rate were assigned 
as weak. Most studies were rated as strong for data collection 
methods, because they used validated and reliable vestibular 
function tests. Nine of the 27 studies (32%) were labeled as 
moderate for this parameter, because the judgement of the test 
results was based on visual evaluation (i.e., Frenzel goggles) 
by a single investigator. In only two studies (Fee 1980; Lerner 
et al. 1986), the researchers were not aware of the administered 
AG. Uncertainty of blinding was rated as moderate. Finally, the 
criteria for selection bias were mostly rated as moderate or weak 
because detailed information about the selection procedure was 
lacking.
Synthesis of the Included Studies
Characteristics of AG-Induced Vestibulotoxicity • In 21 
studies, the prevalence of AG-induced vestibulotoxicity was 
identified. In the other six studies (Deka et al. 1977; Black 
et al. 2004; Ishiyama et al. 2006; Weber et al. 2009; Ahmed 
et al. 2011; Agrawal et al. 2013), the aim was to determine ves-
tibular outcome measures in patients that were selected based 
on their known AG-induced vestibulotoxicity. As presented in 
Supplemental Digital Content 1 (http://links.lww.com/EANDH/
A351), different types of AGs were used. The prevalence of ves-
tibulotoxicity categorized by the type of AG is represented in 
Table 3.
The patients (in the prevalence studies) with reported ves-
tibulotoxicity after AG therapy (n = 117) usually showed 
bilateral vestibular dysfunction (n = 46), although in 6 studies 
Fig. 1. Flowchart presenting a summary of the search results and the reasons 
for exclusion.
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unilateral dysfunction (n = 11) was observed as well (Noone 
et al. 1974; Winkel et al. 1978; Eviatar & Eviatar 1981; Tjern-
ström et al. 1982; Scheenstra et al. 2009; Chen et al. 2013). 
As reported in Supplemental Digital Content 1 (http://links.
lww.com/EANDH/A351), in 14 studies (52%), patients were 
questioned concerning vestibular symptoms after AG adminis-
tration (Tjernström et al. 1973; Noone et al. 1974; Lehmann 
et al. 1976; Deka et al. 1977; Barza et al. 1980; Fee 1980; Lerner 
et al. 1986; Pedersen et al. 1987; Gendeh et al. 1991; Black 
et al. 2004; Ishiyama et al. 2006; Scheenstra et al. 2009; Ahmed 
et al. 2011; Kim et al. 2011). In these studies—except for two 
(Lerner et al. 1986; Kim et al. 2011)—vertigo, dizziness, dis-
equilibrium, and oscillopsia were the most reported symptoms 
(Tjernström et al. 1973; Lehmann et al. 1976; Deka et al. 1977; 
Fee 1980; Black et al. 2004; Ishiyama et al. 2006). In two stud-
ies (Deka et al. 1977; Black et al. 2004), nausea, headache, cog-
nitive impairment, and visual sensitivity were reported as well. 
However, lack of awareness of the vestibular impairment was 
also a frequent finding in other cases (Tjernström et al. 1973; 
Noone et al. 1974; Fee 1980; Lerner et al. 1986; Pedersen et al. 
1987; Scheenstra et al. 2009).
Vestibulotoxicity was accompanied by cochleotoxicity in 9 
(Elfving et al. 1973; Deka et al. 1977; Winkel et al. 1978; Barza 
et al. 1980; Fee 1980; Eviatar & Eviatar 1981; Tjernström et 
al. 1982; Lerner et al. 1986; Black et al. 2004) of 20 studies 
(45%) in which the occurrence of cochleotoxicity was exam-
ined as well (Elfving et al. 1973; Noone et al. 1974; Lehmann 
et al. 1976; Deka et al. 1977; Winkel et al. 1978; Finitzo-Hieber 
et al. 1979; Barza et al. 1980; Fee 1980; Eviatar & Eviatar 
1981; Tjernström et al. 1982; Lerner et al. 1986; Pedersen et al. 
1987; Gendeh et al. 1991; Gendeh et al. 1993; Black et al. 2004; 
Zagólski 2008; Scheenstra et al. 2009; Ahmed et al. 2011; Kim 
et al. 2011; Chen et al. 2013). In one of the studies (Pedersen et 
al. 1987), patients showed AG-induced hearing loss, but it was 
unclear whether these patients were the same as those in whom 
vestibulotoxicity was observed. In the remaining 10 studies, ves-
tibulotoxicity occurred without accompanying cochlear damage. 
Deka et al. (1977) and Kim et al. (2011) noted that vestibulo-
toxic symptoms occurred earlier than cochleotoxic symptoms.
The Vestibular Test Battery • An overview of the tests used 
in the included studies is reported in Supplemental Digital 
Content 1 (http://links.lww.com/EANDH/A351). In 21 stud-
ies (78%), the caloric test was the preferred vestibular function 
test for detecting vestibulotoxicity, and was the only vestibular 
test used in 12 studies (Tjernström et al. 1973, 1982; Noone et 
al. 1974; Lehmann et al. 1976; Deka et al. 1977; Winkel et al. 
1978; Barza et al. 1980; Fee 1980; Hauch et al. 1986; Lerner 
et al. 1986; Pedersen et al. 1987; Gendeh et al. 1991; Gendeh 
et al. 1993; Scheenstra et al. 2009). In the 21 prevalence stud-
ies, the frequency of abnormal caloric responses post-AG ranged 
from 0 to 60%. In four descriptive studies (Deka et al. 1977; 
Black et al. 2004; Ahmed et al. 2011; Agrawal et al. 2013), an 
abnormal caloric response was observed in 75.5 to 100% of the 
cases. In these studies, however, the diagnoses were based on 
the absence of caloric-induced nystagmus. Reduction in the peak 
slow phase velocity (SPV) was the most commonly used cri-
terion for the evaluation of vestibulotoxicity. For example Fee 
(1980) and Lerner et al. (1986) used 33 and 50%, respectively, as 
the minimal reduction of the peak SPV. In the studies by Agrawal 
et al. (2013), Eviatar and Eviatar (1981), and Scheenstra et al. 
(2009), the responses were classified as abnormal if the peak 
SPV did not reach more than 5°/s, 10°/s, or the values did not 
meet the predetermined norms. In a few studies, the SPV could 
not be calculated since the judgement of the vestibular response 
was based on qualitative evaluation (Barza et al. 1980; Tjern-
ström et al. 1982; Hauch et al. 1986; Gendeh et al. 1991; Zagól-
ski 2008; Ahmed et al. 2016). In the study of Pedersen et al. 
(1987), a reduction of at least 25% in the caloric sum was used.
Rotatory chair testing was the second most commonly used 
test of vestibulotoxicity and was also used in eight studies, while 
in four it was the only vestibular test used (Elfving et al. 1973; 
Finitzo-Hieber et al. 1979; Gendeh et al. 1991; Aust 2001). Three 
studies investigated the prevalence of vestibulotoxicity in children 
using the rotatory chair test. The prevalence of abnormal responses 
ranged from 0% (Aust 2001) to 100% (Ishiyama et al. 2006). In 
three descriptive studies (Black et al. 2004; Ishiyama et al. 2006; 
Kim et al. 2011), the rotatory chair parameters were described in 
detail. Black et al. (2004) found abnormal responses in all 33 sub-
jects who were tested with single-sine and pseudorandom rotation 
stimuli. In eight study participants, a normal vestibulo-ocular reflex 
(VOR) gain was found, whereas the time-constant (T
c
) was abnor-
mal. In 23 subjects, both gain and T
c
 were significantly reduced. In 
the study of Ishiyama et al. (2006), a reduced gain and increased 
phase were seen over the entire tested frequency range. However, 
the decrease in VOR gain was greater in the lower frequencies (0.05 
to 0.2 Hz), whereas some patients had preserved gain at intermedi-
ate frequencies (0.8 Hz). Additionally, minimal responses to high 
acceleration step changes in velocity and a bilateral ultralow VOR 
T
c
 could be observed. Kim et al. (2011) observed abnormal VOR 
responses in 2.9% of their study participants. In comparison with 
the control group, VOR gain values were significantly lower at all 
three frequencies tested. Moreover, VOR gain values were signifi-
cantly decreased at higher frequencies (0.04 to 0.16Hz) compared 
with the lower frequency (0.01 Hz).
The horizontal head impulse test (Halmagyi & Curthoys 
1988) was used in five studies in patients with known AG-
induced vestibulotoxicity (Ishiyama et al. 2006; Weber et al. 
2009; Ahmed et al. 2011; Agrawal et al. 2013; Ahmed et al. 
2016). In these studies, except for one (Weber et al. 2009), the 
detection of the catch-up saccades was based on clinical assess-
ment and all patients showed catch-up saccades during head 
impulses to one or both sides. In the study using search coils 
(Weber et al. 2009), bilateral symmetrical reductions of the 
VOR gain, depending on the degree of vestibulotoxicity, were 
TABLE 3. Prevalence of vestibulotoxicity categorized by the 
type of AG in adults and children
Prevalence Adults (%) Children (%)
Patients treated with 
amikacin (n = 101)
7/50 (14.0) 10/51 (19.6)
Patients treated with 
tobramycin (n = 138)
22/138 (15.9) Not tested
Patients treated with 
streptomycin (n = 180)
29/180 (16.1) Not tested
Patients treated with 
gentamicin (n = 390)
34/250 (13.6) 13/140 (9.3)
Patients treated with 
netilmicin (n = 128)
1/91 (1.1) 0/37 (0)
Patients treated with 
kanamycin (n = 118)
Not tested 1/118 (0.8)
AG, aminoglycoside.
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seen in patients with known gentamicin-induced vestibulotox-
icity. Additionally, the overt catch-up saccades were 5.6 times 
larger than in normal subjects.
For the evaluation of otolith organ function, oVEMP and 
cVEMP (Colebatch & Halmagyi 1992; Rosengren et al. 2005) 
were used in only one (Agrawal et al. 2013) and three studies, 
respectively (Zagólski 2008; Agrawal et al. 2013; Chen et al. 
2013). All studies using cVEMP used 500 Hz tone burst to evoke 
a response, whereas the one study that used oVEMP used a mini-
shaker to generate the response. In the study of Agrawal et al. 
(2013), the study participants had bilateral vestibulopathy (BV) 
with different etiologies, including nine with BV secondary to 
AG therapy. Sixty-four and 61% of all patients had a reduction of 
oVEMP and cVEMP amplitude, respectively, in comparison with 
the control group. Although not specifically discussed, the great-
est reduction of vestibular evoked myogenic potential (VEMP) 
amplitude was detected in patients with AG-induced BV. How-
ever, the difference in decreased amplitude was only significant 
in oVEMP testing. In the study of Chen et al. (2013), 3 patients 
(13%) treated with amikacin had abnormal cVEMP amplitudes. 
Zagólski (2008) reported a similar prevalence of absent cVEMP 
responses (14%).
In the context of this review, other nonobjective tests used 
were not described in detail.
As shown in Supplemental Digital Content 1 (http://links.
lww.com/EANDH/A351), only 8/27 (30%) studies using a 
complementary test battery of these multiple objective tests 
(Eviatar & Eviatar 1981; Black et al. 2004; Ishiyama et al. 
2006; Zagólski 2008; Ahmed et al. 2011; Agrawal et al. 2013; 
Chen et al. 2013; Ahmed et al. 2016). Three studies (Eviatar & 
Eviatar 1981; Black et al. 2004; Ahmed et al. 2016) discussed 
both caloric and rotatory test results. The clinical Head Impulse 
test (HIT) and caloric test results were represented in the stud-
ies of Agrawal et al. (2013), Ahmed et al. (2011), and Ahmed et 
al. (2016). Two studies estimated the outcome on both HIT and 
rotatory chair testing (Ishiyama et al. 2006; Ahmed et al. 2016). 
Finally, the studies of Chen et al. (2013) and Zagólski (2008) 
discussed both the prevalence of abnormal caloric test results 
and abnormal cVEMP results. The prevalence of abnormal test 
results categorized by each study is shown in Table 4.
DISCUSSION
Vestibulotoxicity in Humans
The considerable range (0% to 60%) in prevalence of ves-
tibulotoxicity is caused by many factors contributing to the 
amount and severity of AG-induced ototoxic side effects, 
including the type of AG, which may be more or less vestibulo- 
or cochleotoxic (Matz 1993; Selimoglu et al. 2003; Rybak & 
Ramkumar 2007). A systematic review conducted by Kahlme-
ter and Dahlager (1984) reported that among all AG adverse 
effects in clinical studies between 1975 and 1982, the highest 
prevalence of vestibulotoxicity was found in patients who were 
treated with amikacin, tobramycin, and gentamicin. The results 
in the current systematic review support these findings; how-
ever, streptomycin was found to be another important contribu-
tor to AG vestibulotoxicity (Table 3). Although there are many 
studies about vestibulotoxicity of diverse AGs, studies compar-
ing side effects among different AGs are rare (Selimoglu et al. 
2003). Consequently, whether a particular AG is more or less 
vestibulotoxic in humans is unknown.
Factors contributing to the amount of cochleotoxicity include 
pre-existing renal failure, cumulative exposure, duration of AG 
administration, coadministration of known ototoxic drugs, and 
increased age (Govaerts et al. 1990; Forge & Schacht 2000; 
Rogers & Petersen 2011). Unfortunately, evidence to support 
the influence of these risk factors on vestibulotoxicity is scarce 
(Ariano et al. 2008; Rogers & Petersen 2011). For example, 
there is some evidence that vestibulotoxicity due to systemic 
AGs is dose-dependent (Chen et al. 2013) but this finding needs 
to be corroborated. Although discussion of this information falls 
outside the scope of the study’s objective, dosing data is conse-
quently represented in Supplemental Digital Content 1 (http://
links.lww.com/EANDH/A351). However, if these factors also 
contribute to the prevalence of vestibulotoxicity, the reported 
prevalence should be critically evaluated in studies that did not 
control for these confounding variables (Supplemental Digital 
Content 2, http://links.lww.com/EANDH/A352). For example, 
the high upper level (60%) of the overall prevalence range was 
established by a study including only 10 patients with chronic 
renal failure in whom vestibular function tests were performed 
after cumulative exposure to gentamicin (Gendeh et al. 1993). 
On the other hand, in three studies, evidence of vestibulotoxic-
ity was lacking, which may be explained by the use of a very 
low gentamicin dose (Gendeh et al. 1991), a low follow-up rate 
and the use of only one vestibular function test (Hauch et al. 
1986; Aust 2001). Additionally, vestibulotoxicity was poten-
tially under- or overestimated in other studies due to the similar 
flaws. Perhaps more important is the influence of baseline test-
ing, which was lacking in 12 of the 21 prevalence studies and 
most likely resulted in an overestimation of vestibulotoxicity 
(Elfving et al. 1973; Tjernström et al. 1973; Noone et al. 1974; 
TABLE 4. Prevalence of abnormal test results in studies using multiple objective tests
Study
Abnormal Test Results in Patients Receiving AGs
Caloric Test (%) Rotatory Test Clinical HIT (%) cVEMP (%) oVEMP
Agrawal et al. (2013) 9/9 (100) NR 9/9 (100) N/A N/A
Ahmed et al. (2011) 18/18 (100) NR 18/18 (100) NR NR
Ahmed et al. (2016) 10/32 (31) 31% 17/32 (53) NR NR
Black et al. (2004) 24/25 (96) 33/33 (100%) NR NR NR
Chen et al. (2013) 1/23 (4) NR NR 3/23 (13) NR
Eviatar and Eviatar (1981) 5/43 (12) 5/43 (12) NR NR NR
Ishiyama et al. (2006) NR N/A 21/21 (100) NR NR
Zagólski et al. (2008) 6/28 (21) NR NR 4/28 (14) NR
AG, aminoglycoside; HIT, Head Impulse test; N/A, not applicable; NR, not represented in the study; cVEMP, collic vestibular evoked myogenic potential; oVEMP, ocular vestibular evoked 
myogenic potential.
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Finitzo-Hieber et al. 1979; Eviatar & Eviatar 1981; Hauch et al. 
1986; Aust 2001; Zagólski 2008; Scheenstra et al. 2009; Kim et 
al. 2011; Chen et al. 2013; Ahmed et al. 2016).
The prevalence of AG-induced vestibular impairment in 
children is ambiguous as well. Three studies demonstrated a 
similar prevalence as in adults (Eviatar & Eviatar 1981; Zagól-
ski 2008; Chen et al. 2013). In contrast, four studies found little 
or no signs of vestibulotoxicity (Aust 2001; Elfving et al. 1973; 
Finitzo-Hieber et al. 1979). Therefore, Aust (2001) suggested 
that children, and especially neonates, are less sensitive to AG 
adverse effects. However, it has to be noted that most of these 
studies performed examinations several years after the AG ther-
apy (Eviatar & Eviatar 1981) and evaluation of the vestibular 
function was often based on clinical exam or the use of a single 
vestibular test.
Vestibular symptoms are possibly the earliest ototoxic 
effects of systemic AG therapy (Deka et al. 1977; Kim et al. 
2011). However, the symptoms of vestibulotoxicity are usually 
unrecognized and inadequately reported (Halmagyi et al. 1994; 
Liu et al. 2015). This may be attributed to the bilateral nature 
of toxicity-induced vestibular deficits, resulting in rather vague 
symptoms, as reported in the current review (Deka et al. 1977; 
Black & Pesznecker 1993; Black et al. 2004; Ishiyama et al. 
2006; Ahmed et al. 2011; van de Berg et al. 2015; Lucieer et al. 
2016). Additionally, the patient may relate these symptoms to 
the underlying (often life-threatening) disease for which the AG 
treatment is given. Moreover, most of these patients are bedrid-
den and symptoms will not be noticed until they start walking 
(Ahmed et al. 2012), resulting in a delayed onset of symptoms 
(Deka et al. 1977; Ahmed et al. 2011; Kim et al. 2011). In con-
clusion, since symptoms of AG-related vestibulotoxicity are 
rather vague, clinicians should specifically inquire about mul-
tiple vestibular symptoms (not only vertigo) after AG adminis-
tration, as vestibular symptoms can have a considerable impact 
on someone’s quality of life (Mendel et al. 1999; Zingler et al. 
2009; Guinand et al. 2012; Sun et al. 2014; van de Berg et al. 
2015).
As reported by several included studies, a significant amount 
of patients did not experience co-existing hearing impairment, 
suggesting that vestibulotoxicity can occur without accompany-
ing cochleotoxicity (Noone et al. 1974; Lehmann et al. 1976; 
Finitzo-Hieber et al. 1979; Gendeh et al. 1991; Gendeh et al. 
1993; Scheenstra et al. 2009; Zagólski 2008; Ahmed et al. 2011; 
Kim et al. 2011; Chen et al. 2013). Therefore, it is also impor-
tant to screen for cochleo- and vestibulotoxicity separately 
(Dobie et al. 2006; Ahmed et al. 2012; Liu et al. 2015).
The Vestibular Test Battery
Histologic examinations demonstrate that AGs can affect 
the whole vestibular sensorineural epithelium, with type I hair 
cells considered most susceptible components (Lindeman 1969; 
Black & Pesznecker 1993; Nakashima et al. 2000; Tsuji et al. 
2000; Rybak & Ramkumar 2007; Zingler et al. 2009). Addition-
ally, several histological and animal studies reported that the 
SCCs are more vulnerable to toxicity than the otolith organs 
(Lindeman 1969; Nakashima et al. 2000; Tsuji et al. 2000; Ishi-
yama et al. 2007; Sun et al. 2015).
For the detection of vestibulotoxicity, the majority of the 
included studies used caloric and rotatory chair testing, tests 
capable of examining the low- and mid-frequency range of the 
horizontal canal function, respectively (Wuyts et al. 2007; Gon-
çalves et al. 2008; Maes et al. 2011; van de Berg et al. 2015). 
For caloric testing, the most important indication for vestibu-
lotoxicity is a reduction in the SPV of the caloric-induced nys-
tagmus (Tjernström et al. 1973; Barza et al. 1980; Eviatar & 
Eviatar 1981; Lerner et al. 1986; Pedersen et al. 1987; Gendeh 
et al. 1991; Gendeh et al. 1993; Ahmed et al. 2011; Agrawal 
et al. 2013; Chen et al. 2013). In the study of Pedersen et al. 
(1987), the summated SPV was used as a criterion. Several 
studies concerning bilateral vestibular impairment endorse the 
use of caloric sum and suggest a limit of 20°/s to establish the 
diagnosis of bilateral vestibular dysfunction of the horizontal 
SCC (Hain et al. 2013; van de Berg et al. 2015). For rotatory 
chair testing, a reduction in VOR gain and reduced time-con-
stant (T
c
) or increased phase are the most reported findings. 
To screen for BV, some suggest using changes of the VOR 
T
c
 (or phase), rather than gain, which is influenced by the level 
of alertness of the patient (Li et al. 1991; Maes et al. 2008; van 
de Berg et al. 2015).
Over the past few years, new vestibular testing techniques 
have emerged, such as the video HIT and VEMP which pro-
vide complementary information to caloric and rotatory testing, 
because VEMP techniques examine the otolith function (both 
saccule and utricle) and the video HIT provides additional high-
frequency information for each semicircular canal. Therefore, 
clinicians are now able to evaluate the function of all five dif-
ferent vestibular components. The HIT especially serves high-
frequency characterization of the horizontal, posterior, and 
anterior SCC and seems to activate irregular afferents, which 
tend to innervate type I hair cells (Goldberg 2000; Wuyts 2008; 
McCaslin et al. 2015). To date, only five studies use the HIT 
(four used the clinical, subjective, HIT, and one the video HIT) 
for the detection of AG-induced vestibulotoxicity, all showing a 
positive HIT on one (Ahmed et al. 2011) or both sides (Ishiyama 
et al. 2006; Weber et al. 2009; Ahmed et al. 2011; Agrawal et al. 
2013; Ahmed et al. 2016). Only one study (Weber et al. 2009) 
assessed quantitative video HIT (vHIT), reporting larger ampli-
tudes of catch-up saccades than in normal subjects and a bilat-
eral symmetrical reductions of VOR gain. Because the major 
affinity of AGs for type I SCC hair cell dysfunction is well 
known, vHIT seems promising and requires further research 
with implementation of high-speed video goggles and evalua-
tion of the vertical SCCs as well. Cervical and ocular VEMPs 
can examine the integrity of type I saccular and utricular hair 
cells, respectively (Lue et al. 2009; Agrawal et al. 2013; Cur-
thoys et al. 2014), and were so far only used in three vestibulo-
toxicity studies (Zagólski 2008; Agrawal et al. 2013; Chen et al. 
2013). As can be seen in the results, these three studies found a 
loss of the saccular function, with a similar prevalence for chil-
dren treated with AGs (Zagólski 2008; Chen et al. 2013). Since 
the study of Agrawal et al. (2013) compared different etiologies 
of BV, the authors did not report the prevalence of saccular or 
utricular dysfunction of patients with AG-induced vestibulotox-
icity separately. However, due to the comparison of the differ-
ent etiologies, the study showed that oVEMP results should be 
implemented in the screening for AG-induced. oVEMP ampli-
tudes were significantly lower in patients with vestibulotoxic-
ity due to AGs, which means that measurement of the utricular 
function is important for the differential diagnosis of patients 
with BV. For cVEMP, a reduction of both latency and peak to 
peak amplitudes was reported, whereas a reduction of the N1 
Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 VAN HECKE ET AL. / EAR & HEARING, VOL. 38, NO. 6, 653–662 659
oVEMP amplitude was seen in the study of Agrawal et al. Since 
both the raw oVEMP amplitude (N1) and peak to peak cVEMP 
amplitude have shown to provide the most reliable information, 
both parameters can be used for the detection of vestibulotoxic-
ity (Venhovens et al. 2015).
A study that assesses function of each vestibular end organ 
would be particularly clinically relevant. As can be seen in the 
results (Table 4), few studies assess multiple vestibular end 
organs. However, based on this data, some preliminary sugges-
tions for screening can be made. Supported by studies using 
both caloric and rotation tests, AG administration appears to 
cause similar damage to both low- and mid-frequency func-
tion of the HSCC (Eviatar & Eviatar 1981; Black et al. 2004; 
Ahmed et al. 2016). This is in contrast to the high-frequency 
horizontal canal function, which seems to be more affected 
after AG administration in the studies of Agrawal et al. (2013) 
and Ahmed et al. (2011). It should be noted however that the 
study subjects of Agrawal et al. and Ahmed et al. were selected, 
based on abnormal HIT and caloric responses. In these stud-
ies, therefore, all vestibulotoxic patients had both absent caloric 
responses in combination with bi- or unilateral positive HIT 
results. In the prospective study of Ahmed et al. (2016), posi-
tive clinical HIT responses were seen in 53% (17/32) of the 
patients, whereas 31% had pathological caloric and rotation 
outcomes after administration of streptomycin. Additionally, in 
the study of Ishiyama et al. (2006), the authors established that 
all patients had a positive bilateral HIT, whereas a few patients 
did have preserved gain results at intermediate frequencies and 
low accelerations by rotational testing while no response to high 
acceleration step changes could be observed. These findings 
are in agreement with the findings of histopathological studies 
demonstrating that type I hair cells (high-frequency detection) 
of the SCC are more vulnerable to AGs toxicity than other ves-
tibular structures (Lindeman 1969; Black & Pesznecker 1993; 
Nakashima et al. 2000; Tsuji et al. 2000; Rybak & Ramkumar 
2007; Zingler et al. 2009).
Two studies using caloric testing also represented the preva-
lence of abnormal otolith function by using the cVEMP tech-
nique, which revealed conflicting data (Zagólski 2008; Chen 
et al. 2013). One study suggested that AG therapy causes 
damage to both SCC and otolith function, but function of 
the former structure is more frequently impaired. The other 
study discussed that 13% of the patients had abnormal VEMP 
responses, while only 4% of the patients suffered from SCC 
dysfunction (Chen et al. 2013). These latter findings can be 
supported by current histological studies, which suggest that 
type I hair cells (VEMP) are more affected in case of vestibu-
lotoxicity. However, studies using VEMP techniques are too 
limited or different to compare and to draw any definite conclu-
sion. The study of Agrawal et al. (2013) estimated the cVEMP 
and oVEMP results as well, although no prevalence data could 
be compared because the authors did not represent the test 
results of patients with vestibulotoxicity separately from the 
overall group of patients with BV.
Based on these studies (and histological findings) and since 
vHIT and VEMP techniques tend to measure the type I hair cell 
function, both these tests seem promising for the detection of 
AG-induced vestibulotoxicity, in addition to caloric and rota-
tory testing (Fee 1980; Black et al. 2004; Ishiyama et al. 2006; 
Zagólski 2008; Weber et al. 2009; Petersen et al. 2013).
To confirm the diagnosis of vestibulotoxicity, these objec-
tive vestibular tests can be extended with other tests, such as 
the dynamic visual acuity and vestibulospinal reflex tests (e.g., 
Romberg test; Demer et al. 1994; Fujimoto et al. 2009), which 
are frequently recommended to establish the diagnosis of bilat-
eral vestibular impairment (Minor 1998; Fujimoto et al. 2009; 
Ahmed et al. 2011; van de Berg et al. 2015). Additionally and 
of crucial importance is the performance of a thorough history 
taking.
The authors recommend to perform vestibular examination 
before, during, and after AG administration for adequate screen-
ing and close follow-up in patients receiving AGs (Tjernström 
et al. 1973, 198; Minor 1998; Black et al. 2001; Ishiyama et al. 
2006). Baseline testing is necessary to detect subtle or exclude 
pre-existing vestibular dysfunction (Lehmann et al. 1976; Fee 
1980; Black et al. 2004). Because literature suggests that early 
detection of vestibulotoxicity and cessation of the AG adminis-
tration (if possible) can prevent further deterioration of the ves-
tibular system (Black et al. 2004; Ishiyama et al. 2006; Ariano 
et al. 2008; Scheenstra et al. 2009; Kim et al. 2011; Leis et al. 
2015), the vestibular assessment should be performed weekly if 
possible, during therapy (Fee 1980; Minor 1998; Ahmed et al. 
2011). In some cases, vestibulotoxicity effects and vestibular 
function recovery can occur after cessation of the AG therapy 
(Deka et al. 1977; Lehmann et al. 1976; Winkel et al. 1978; Fee 
1980; Black et al. 2001; Black et al. 2004; Kim et al. 2011), 
follow-up testing should be performed for at least 6 months to 
1 year after AG therapy (Black et al. 2001, 2004; Vasquez & 
Mattucci 2003).
Limitations and Recommendations for Further 
Research
To date, there are several flaws in the published literature 
about vestibulotoxicity in humans. The current review shows 
that the existing evidence is insufficient to estimate the preva-
lence of AG vestibulotoxicity in adults and children, to identify 
the most vestibulotoxic AG type and to figure out whether the 
known risk factors for ototoxicity also apply to vestibulotoxic-
ity. Furthermore, based on the present literature, it is impos-
sible to determine the part of the vestibular system that is most 
sensitive for AGs, because the current evidence is mainly based 
on evaluation of the horizontal SCC. Moreover, data compar-
ing rotation or vHIT results with VEMP outcomes are lacking 
and studies using a complete vestibular test battery in the same 
study subject(s) have not been performed.
The current systematic review also has several limitations. 
First, a meta-analysis could not be performed because of the 
large heterogeneity in study methodologies. Second, a signifi-
cant portion of the included studies had a low methodological 
quality. Nevertheless, studies at high risk for bias were included 
as well, to provide additional information for the current review. 
Finally, because non-English articles were excluded, language 
bias may have occurred.
In conclusion, the data presented in this review encourages 
close vestibulocochlear follow-up of patients before, during, 
and after AG treatment and demonstrates the importance of 
developing specific screening protocols. As to which test would 
be the most appropriate for the early detection of vestibulotox-
icity, no definite conclusion can be drawn as a large variation 
as well as conflicting results have been reported and the current 
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evidence is mainly based on evaluation of the horizontal SCC 
alone. However, as stated earlier, in accordance with animal 
and histopathological studies, the current literature suggests 
that type I hair cells of the semicircular canals are most vulner-
able to toxicity. vHIT and VEMP testing therefore seem the 
most promising for the detection of AG-induced vestibulotox-
icity, in addition to caloric and rotatory chair testing. Moreover, 
these tests are short, easy to perform, and can be performed in 
children, all of which are convenient advantages for patients 
who are bedridden or too ill for studies requiring more equip-
ment such as caloric and rotatory chair testing. Additionally, 
the findings of this systematic review clearly emphasize the 
need for future high-quality prospective longitudinal studies 
including all above complementary objective vestibular tests 
and taking into consideration the discussed possible confound-
ing factors, as pre-existing renal failure, cumulative exposure, 
duration of AG administration, coadministration of known oto-
toxic drugs, increased age, and possible genetic susceptibility, 
to compare the sensitivity of the vHIT and VEMP techniques 
for the early detection of vestibulotoxicity to the caloric and 
rotatory test.
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